Ballal Rahul D.

October 13, 2026

AGIO Valuation Concerns Ahead of Q3 2026 Call. AGIO’s November earnings call sparked debate that the shares might be undervalued by about 28%, while analysts noted the stock appears fully priced against current sales. The company will host its third‑quarter 2026 results call on Nov. 5, which could clarify expectations. After a 29% decline over three months, Truist Securities lowered its target price to $37, reflecting a more cautious view.

October 11, 2026

Enliven's ENABLE-2 Trial Design Sparks New Questions. Enliven Therapeutics has clarified the design of its ENABLE-2 Phase 3 trial for relcobatinib in chronic myeloid leukemia, following questions raised by the trial’s structure. The company also confirmed FDA alignment on the study, while a separate patent dispute involving Halozyme and Merck has kept the leukemia treatment landscape in focus. These developments highlight the regulatory and strategic challenges Enliven faces as it moves toward clinical milestones.